Marker Therapeutics (NASDAQ:MRKR) Announces Earnings Results, Beats Estimates By $0.02 EPS

Marker Therapeutics (NASDAQ:MRKR) released its earnings results on Friday. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02, FiscalAI reports. Marker Therapeutics had a negative return on equity of 80.86% and a negative net margin of 343.03%.The company had revenue of $0.75 million for the quarter, compared to the consensus estimate of $0.68 million.

Marker Therapeutics Stock Performance

Shares of MRKR stock traded down $0.04 during trading hours on Friday, hitting $1.42. The company had a trading volume of 28,062 shares, compared to its average volume of 234,915. Marker Therapeutics has a 12 month low of $0.81 and a 12 month high of $4.07. The firm has a market capitalization of $23.67 million, a price-to-earnings ratio of -1.67 and a beta of 1.43. The firm’s fifty day moving average is $1.44 and its 200 day moving average is $1.43.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Osaic Holdings Inc. boosted its holdings in shares of Marker Therapeutics by 16.5% in the 4th quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after acquiring an additional 13,340 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Marker Therapeutics by 16.4% during the 4th quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock worth $184,000 after buying an additional 17,400 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Marker Therapeutics in the 2nd quarter valued at $33,000. LPL Financial LLC lifted its stake in shares of Marker Therapeutics by 41.7% in the 4th quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock valued at $124,000 after purchasing an additional 24,500 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of Marker Therapeutics in the 3rd quarter valued at $25,000. 22.39% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Marker Therapeutics in a research report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Marker Therapeutics currently has an average rating of “Hold” and a consensus price target of $10.00.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.